Recursion Pharmaceuticals, Inc.
- RXRX
- NASDAQ
- Biotechnology
- AI-Driven Drug Discovery
- Clinical-stage Biotechnology
$3.61
Today +4.18%Quote Oct 19, 2026, 08:00 PM UTC
−5.74%over the last month
Max drawdown −27.4%From 1-month high −24.5%3 months +17.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
Where the money comes from
Q2 2026 revenue $7.7M
- License and Service$7.3M95.2%
- Grant$367,0004.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
600
Founded
2013
Market value
$1.93B
Quote Oct 19
Analyst target
$5.90
+63.4% from here
Floor
$3.57
1.0% below price
Resistance
$3.77
4.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RXRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free